Published in final edited form as:
Front Biosci. ; 14: 1152–1168.

Role of resident CNS cell populations in HTLV-1-associated neuroinflammatory disease

Veronique Lepoutre, Pooja Jain, Kevin Quann, Brian Wigdahl, and Zafar K. Khan

Department of Microbiology and Immunology, and Center for Molecular Virology and Neuroimmunology, Center for Cancer Biology, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102, USA

Abstract

Human T cell leukemia virus type 1 (HTLV-1), the first human retrovirus discovered, is the etiologic agent for a number of disorders; the two most common pathologies include adult T cell leukemia (ATL) and a progressive demyelinating neuroinflammatory disease, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The neurologic dysfunction associated with HAM/TSP is a result of viral intrusion into the central nervous system (CNS) and the generation of a hyperstimulated host response within the peripheral and central nervous system that includes expanded populations of CD4⁺ and CD8⁺ T cells and proinflammatory cytokines/chemokines in the cerebrospinal fluid (CSF). This robust, yet detrimental immune response likely contributes to the death of myelin producing oligodendrocytes and degeneration of neuronal axons. The mechanisms of neurological degeneration in HAM/TSP have yet to be fully delineated *in vivo* and may involve the immunogenic properties of the HTLV-1 transactivator protein Tax. This comprehensive review characterizes the available knowledge to date concerning the effects of HTLV-1 on CNS resident cell populations with emphasis on both viral and host factors contributing to the genesis of HAM/TSP.

Keywords

CNS; HTLV-1; Virus; TSP; HAM; CSF; Review

2. INTRODUCTION

Human T cell leukemia virus type 1 (HTLV-1) is a type C retrovirus primarily endemic to Japan, Central and South America, the Middle East, regions of Africa, and the Caribbean (1-7). Currently, an estimated 10–20 million people worldwide are infected with this virus (8-10). Although the majority of infected individuals remain asymptomatic, HTLV-1 is the causative agent of a number of disorders, notably adult T cell leukemia (ATL) and a progressive demyelinating neurologic disorder, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) (11). HTLV-1 presents as either ATL or HAM/TSP in approximately 2–3% of seropositive individuals after a long asymptomatic period of latency (12). The likelihood of a small percentage of HTLV-1-infected patients developing HAM/TSP has been postulated to be dependent on several factors including human histocompatibility leukocyte antigen (HLA) subtype (13), viral strain (14-16), mode of infection (17), and proviral DNA load (18-22). In addition to ATL and HAM/TSP, HTLV-1

Send correspondence to: Zafar K. Khan, Department of Microbiology and Immunology, and Center for Molecular Virology and Neuroimmunology, Center for Cancer Biology, Institute for Molecular Medicine & Infectious Disease, Drexel University College of Medicine, 245N, 15th St., 18th Floor, Philadelphia PA 19102, Tel: 215-762-3719, Fax: 215-762-1955, E-mail: zkhan@drexelmed.edu.

has been associated with a spectrum of extraneural inflammatory disorders such as pulmonary alveolitis, dermatitis, Sjogren's syndrome, Becet's Disease, thyroid disease, prostatitis, cystitis (23), uveitis, arthritis, hepatitis (24), polymyositis, HTLV-1-associated arthropathy, and a syndrome clinically indistinguishable from sarcoidosis (25).

3. HTLV-1-ASSOCIATED MYELOPATHY/TROPICAL SPASTIC PARAPARESIS (HAM/TSP)

The predominant neurological disorder caused by HTLV-1, HAM/TSP, is a chronic progressive inflammatory disease with many similarities to multiple sclerosis. Pathologically, HAM/TSP is manifested as a demyelinating disorder involving degradation of white matter within the lateral funiculi spinal cord, mainly concentrated in the thoracic and lumbar segments of tissue. Degeneration has also been described in the cervical spinal cord and the brainstem, although this may be due to secondary damage from Wallerian degeneration (26, 27). The main area of neuronal damage has been observed within the corticospinal tract, with the majority of patients citing weakness of lower limbs as the first symptom (28). Clinically, HAM/TSP presents as a spastic paraparesis with common symptoms including lower back pain as well as urinary and sexual dysfunction (11, 29, 30). HAM/TSP is three times more likely to affect women than men (11, 29) and the disease progresses at a faster rate in women than in men. Progression is further increased if disease onset occurs before menopause, suggesting that hormones may be involved (31). HAM/TSP often occurs in two phases, initiated first as an inflammatory disorder, followed by a chronic long-term degenerative stage (32). Although there are a multitude of factors that are involved in the development and progression of HAM/TSP, symptomatic patients typically demonstrate the presence of HTLV-1-specific antibodies and infiltrating T lymphocytes in the peripheral blood and cerebrospinal fluid (CSF) accompanied by the release of proinflammatory cytokines (33, 34). This inflammatory response compromises the integrity of the blood-brain barrier (BBB) and increases the potential for further lymphocyte trafficking into the CNS (35-38). CD8⁺ cytotoxic T lymphocyte (CTL) cells specific for the HTLV-1 transactivator protein Tax, especially the Tax11–19 amino acid epitope, have been shown to be the primary proliferating cell type in HAM/TSP (39). Later stages of the disease are marked by the presence of extracellular Tax and expanding Tax-specific CTLs in the CSF (40-43).

There are several contributing mechanisms postulated to be involved in the demyelination and CNS cell death that occurs in the spinal cord of HAM/TSP patients: the direct damage mechanism, the bystander mechanism, and the autoimmune mechanism of molecular mimicry (44). The direct damage mechanism involves damage caused by infiltrating activated CD8⁺ CTL cells specific for Tax. The persistent activation of CD8⁺ T cells in the CNS suggests the continued presence of replicating virus or viral proteins (45). Cellular damage in the direct damage model results from the targeted lysis of infected cells and release of inflammatory molecules. The bystander damage mechanism involves the damage in the CNS that is caused by cytotoxin release, specifically proinflammatory cytokine release, by the infiltrating lymphocytes and resident cell populations in response to the presence of HTLV-1 (46). Proinflammatory cytokines such as tumor necrosis factor- α (TNF- α) and interferon- γ (IFN- γ) are postulated to cause dysfunction and death to resident cells of the CNS with further disruption of the BBB (47). In addition, HTLV-1-associated pathogenesis within the CNS may be associated with an autoimmune mechanism involving molecular mimicry. An immune response generated to the viral protein Tax was found to cross-react with the neuronal antigen heterogeneous ribonuclear protein-A1 (hnRNP-A1) (44, 48). Thus, a CTL response directed against Tax could lead to the incidental lysis of hnRNP-A1-presenting cells in the CNS.

4. CNS RESIDENT CELL POPULATIONS AND HAM/TSP

A number of the resident CNS cell populations during the course of HAM/TSP have been shown to be susceptible to viral infection. Based on numerous *in vitro* studies, animal model investigations, and studies performed in human tissues, the existence of latent, persistent, and productive viral infection of resident cell populations is likely but the extent and the role of these infected cell populations with respect to the etiology of HAM/TSP remains under investigation (17, 49). In general, the main targets for viral infection are thought to be the cell populations responsible for regulating the BBB such as astrocytes, microglia, and peripheral immune cells. Oligodendrocytes and neurons, which form the core of the CNS, are also potential targets for HTLV-1. Experiments performed *in vitro* have successfully infected astrocytes, macrophages, microglia, and neurons with HTLV-1 (50), yet *in situ* PCR hybridization has localized proviral DNA in the CNS only to astrocyte cell populations and infiltrating CD4⁺ T lymphocytes (20, 51), which have been postulated to be nonproductively infected. However, there exists the possibility that proviral DNA is present in other cell types but at levels below the limits of detection (17). The susceptibility of the resident CNS cell types to HTLV-1 infection and subsequent viral gene expression likely leads to cellular dysfunction coupled with clinically apparent neurologic dysfunction. In addition, viral-induced alterations in these cells may play important roles in the progression of HAM/TSP. However, very little information exists concerning the molecular mechanisms of HTLV-1 LTR activation and/or viral gene expression in the secondary target cell populations. Several members of the C/EBP family are expressed at high levels in cells of the monocyte-macrophage lineage (52) and are intimately involved in the regulation of myelocytic-monocytic gene expression. Recently it was shown that basal activation of HTLV-1 LTR was enhanced by the overexpression of C/EBP β , C/EBP δ , or C/EBP ϵ , whereas Tax-mediated transactivation was inhibited by the overexpression of C/EBP α and C/EBP β , and to a lesser extent by C/EBP δ (53). This has indicated that cells expressing high levels of C/EBP factors such as some of those within the myeloid lineage are less permissive to HTLV-1 gene expression. In addition, the AP-1 family of transcription factors was also shown to modulate HTLV-1 LTR activation during phorbol ester-induced differentiation of monocytes from the CD34⁺ progenitor cells (54). The binding sites for another family of transcription factors (Sp1-Sp4) have also been identified within the U3 region of the HTLV-1 LTR (55). Both Sp1 and Sp3 were found to inhibit basal and Tax-mediated LTR activation by binding to Tax responsive element 1 (TRE-1) repeat III (55). Therefore, trafficking of latently and/or persistently infected monocytes can lead to viral transmission to the CNS and infection of resident cell populations.

4.1. Perivascular cells, macrophages, and microglia

Perivascular cells are derived from bone marrow monocytes and possess the ability to differentiate into a number of cellular phenotypes. These cells are located in the vascular area surrounding vessels supplying oxygenated blood to the CNS, which forms a bridge or link between the immune system within the peripheral blood and associated lymphoid tissues and the immune surveillance system within the CNS. Perivascular macrophages express major histocompatibility complex (MHC) class II antigens and are known to possess phagocytic properties and the ability to act as antigen presenting cells (APCs) (56, 57). These cells display a high turnover rate and may proliferate in circumstances associated with CNS inflammation. During the course of HAM/TSP, a small percentage of peripheral blood monocytes are infected, which enter the CNS as macrophages and perivascular microglia as they are replenished (58, 59). There are two populations of resident microglia in the CNS that include the perivascular and parenchymal microglia. Perivascular microglia reside near the CNS blood vessels and have a high turnover rate whereas parenchymal microglia have a lower turnover rate, surviving for nearly the life of the individual (59). Microglial cells

function as the primary immune cell population within the CNS. These are macrophage-like cells of monocyte origin able to function as both APCs and phagocytes (60). The parenchymal microglial cells are normally a quiescent, small cell population within the CNS, able to replicate under inflammatory circumstances and acquire a reactive phenotype, a process also known as microgliosis (61). Unlike perivascular microglial cells, parenchyma microglia do not express major histocompatibility complex (MHC) class I or II in their quiescent state (57, 62-64). Positive correlations have been demonstrated between the HTLV-1 proviral DNA load and macrophage and microglia cellular activation (65). Hoffman *et al* successfully infected a monocyte cell line, microglia, and blood-derived macrophages with HTLV-1 *in vitro* in several mixed culture conditions. Their results suggested the ability of microglia and macrophages to harbor proviral DNA during chronic infection, but *in situ* hybridization has not corroborated these results *in vivo* as of yet (51, 66-69). Microglia have also been successfully transduced with Tax *in vitro*, subsequently releasing inflammatory cytokines including TNF- α , interleukin (IL)-6 and IL-1 β , potentially contributing to the demyelination in the pathogenesis of HAM/TSP (70).

4.2. Astrocytes

Astrocytes are the most abundant CNS resident cells and are involved in the maintenance of the physical integrity of the BBB. Astrocytes mediate the physiological environment of the CNS through their contribution to the BBB, as well as provide nutrient factors to neuronal cells, maintain the structural integrity of the CNS, and prevent incidence of cell death through excitotoxicity by the uptake of the excitatory transmitter glutamate (71-73). Astrocytes are also thought to have the capacity to function as immune cells together with microglia, and are controversially suggested to act as non-professional APCs (64). Activation of these cells induces the secretion of proinflammatory cytokines and chemokines, and subsequently the recruitment of antigen-specific CD4⁺ and CD8⁺ T-cells from the periphery (74). Due to the sheer number of astrocytes, the variety of functions performed, and their importance to the CNS environment, they have been examined with respect to their potential role in the genesis of HAM/TSP. The proximity of the astrocytes to the BBB places these cells in a vulnerable position to be infected through cellular contact with infiltrating HTLV-1-infected lymphocytes and/or monocyte-macrophages. *In situ* hybridization studies have localized HTLV-1 Tax RNA in the CNS to astrocytes, suggesting that astrocytes may also be a source of extracellular Tax in the CNS through secretion (51). In support of these observations, we have also demonstrated the secretion of the HTLV-1 Tax protein from astrocytes cultured *in vitro* (unpublished observations). Banerjee *et al* performed an *in vitro* Tax transduction of an astrocytoma cell line that resulted in both the release of proinflammatory cytokines as determined by a proinflammatory cytokine array. These studies also demonstrated that serum-starved primary astrocytes were sensitive to apoptosis when treated with Tax (75). Tax- and TNF- α -treated reactive astrocytes have also been shown to downregulate their uptake of glutamate and catabolism to glutamine by the decreased mRNA expression of glutamate transporters, thereby potentially contributing to the increased incidence of neuronal and oligodendrocyte death or dysfunction by excitotoxicity (76). Relevant to these *in vitro* studies, additional *in vitro* experiments have suggested that HTLV-1 infection of astrocytic cultures results in the initial production of infectious virus with the subsequent establishment of a latent infection (77-81). This infection may be temporarily reactivated by the administration of proinflammatory cytokines (78, 82). Overall, the available evidence has suggested that astrocytes may act as a viral reservoir within the CNS (83).

4.3. Neurons

Although neurons are not believed to harbor virus *in vivo* (51), the potential for HTLV-1 neuronal infection *in vitro* was demonstrated by the infection of a neuroblastoma cell line,

and a neuronal cell line of non-tumorigenic origin, HFGC and HCN-1a (84). The presence HTLV-1 surface antigens was verified by *in situ* hybridization and flow cytometry (85). As discussed previously, another reported mechanism of neuronal damage in HAM/TSP may be due to the autoimmune pathology of molecular mimicry, which as been shown to involve the recognition by the immune system of a host antigen as a viral protein. Host targets have been demonstrated to be the hnRNP-A1 neuronal self-antigen, a nuclear riboprotein, and the similar but shorter hnRNP-A1^B. These proteins have been identified as cross-reacting with anti-Tax antibodies, suggesting that Tax and neuronal proteins share some sequence homology. The molecular mimicry may lead to a CTL response directed against neuronal populations (27, 86). The cross-reactivity and presence of autoantigens may contribute to the pathogenesis of HAM/TSP, but is unlikely the primary cause, as hnRNP-A1 is not confined to the CNS nor easily detected (87). To examine the effect of extracellular Tax on neurons, the neuronal cell line NT2-N was treated with soluble Tax. The treatment of these cells with Tax, even for time periods as short as 5 min, resulted in gene expression and secretion of TNF- α . These results have suggested that neurons subjected to Tax *in vivo* may contribute to the immune pathogenesis of HAM/TSP (88).

4.4. Oligodendrocytes

As stated previously, the pathogenesis of HAM/TSP has been shown to involve a progressive demyelination resulting from the dysfunction and death of the CNS myelinating cell, the oligodendrocyte. Myelin is a fatty protein, composed of layers of plasma membrane that insulate axons and increase the speed of conduction and accuracy of neuronal electrical action potential impulses (89). In diseases such as multiple sclerosis (MS), it is generally thought that axonal degeneration will follow demyelination (90). There are two theories concerning the demyelination that occurs in HAM/TSP. The first, or “outside-in” theory, assumes that the oligodendrocyte damage occurs primary to the axonal degeneration (91). Moore *et al.* hypothesized that infiltrating CD8⁺ T cells are responsible for the dysfunction and death of oligodendrocytes by the release of proinflammatory cytokines, and by the lysis of infected cells (26). Oligodendrocytes are inherently sensitive cells to the effects of TNF- α , one of the proinflammatory cytokines released by infiltrating CD8⁺ T cells (43, 47, 92, 93). Extracellular Tax is able to induce proinflammatory cytokine secretion from the resident CNS cell populations as well, contributing to the dysfunction of oligodendrocytes. The “inside-out” theory, however, suggests that the axonal dysfunction occurs prior to the oligodendrocyte dysfunction. In this theory, the axonal degeneration is the primary pathology and oligodendrocyte death is a subsequent occurrence (91). Banerjee *et al.* demonstrated that an oligodendroglioma cell line will secrete the proinflammatory cytokines IL-1 β , TNF- α , TNF- β , and IL-6 when transduced by Tax, as determined by cytokine array experimentation. Regardless of whether damage is caused by an “outside-in” or “inside-out” mechanism, the oligodendrocyte plays an integral role in the genesis of HAM/TSP (75). A summary of the CNS resident cells with respect to the genesis of HAM/TSP is shown in Table 1.

5. VIRAL FACTORS

Previous studies have suggested that the mode by which primary infection occurs is a potential factor that may determine whether an infected carrier progresses to develop ATL or HAM/TSP. An infection occurring through the peripheral blood, such as would occur through intravenous drug use, leads to the shuttling of CD4⁺ infected T-cells to the bone marrow where they may subsequently transfer infectivity to progenitor cells as well as lymphoid and myeloid precursor cells populations. These cells then elicit tax-specific immune responses and cross over into the BBB to cause HAM/TSP (17, 94). Primary infection via mucosal linings, as would occur through sexual contact, involves the infection of APCs first, where they shuttle to lymph nodes and subsequently transfer infectivity to T

cell populations, a weak HTLV-1-specific response is created and the T cells are allowed to proliferate ultimately leading to ATL (17). In addition to the cellular dysfunction resulting from viral replication within specific cell populations, viral proteins, such as Tax as well as other retroviral proteins, when secreted into the extracellular environment may be capable of causing damage independent of the direct damage caused by viral replication and that due to the immune response to infection. This section will discuss many of the viral factors associated with HTLV-1, including viral transmission and infection, and actions of Tax that are necessary for viral infection such as the transcriptional and extracellular effects of Tax. Host-viral interactive factors proposed to contribute to the development of HAM/TSP, such as mode of infection, HLA alleles, and proviral load are also included.

5.1. Viral transmission

Similar to HIV-1, HTLV-1 has a tropism for CD4⁺ T-cells, although CD8⁺ T cells (21), monocytes, dendritic cells (DCs) (58, 95-98), and as discussed previously, resident CNS cell populations, are susceptible to infection as well. The infection may occur through a variety of mechanisms. Infection of HAM/TSP patients involves a latent infection of the bone marrow compartment that is extended to the periphery through the process of hematopoiesis, possibly contributing to the viral burden in the CD4⁺ T cell, CD8⁺ T cell, macrophage, and DC compartments in the peripheral circulation and tissues (99, 100). A general feature associated with HTLV-1 infection involves the spontaneous proliferation of peripheral blood mononuclear cells when cultured *in vitro*. In HAM/TSP patients, this proliferation involves, to a large extent, virus-infected CD8⁺ T cells (39). The mechanism of proliferation appears to involve the impact of Tax on the cell cycle and the increased release of IL-2 (101). The expansion of proviral DNA by cellular proliferation rather than by viral replication involving the activity of reverse transcriptase probably accounts for the genetic stability in the proviral DNA load observed compared to other retroviral infections such as those involving HIV-1 (102). In contrast to the hyperstimulated T cell response invoked by HTLV-1 infection, HIV-1 viral infection impairs the proliferation of CD4⁺ T cells; there is in fact, a proliferation defect following receptor stimulation (103-106), followed by a decrease in IL-2 production and a progressive depletion of CD4⁺ T cells resulting from greater susceptibility to apoptosis (103, 107-109). Direct HTLV-1 infection occurs via cell-to-cell contact rather than by cell-free virus, as only 1 in 10⁵ free virions is infectious (110-112). It is generally thought that the low efficiency of the HTLV-1 virion infection involves a unique frameshifting that occurs in the synthesis of the reverse transcriptase. The Gag-Pol-Pro precursor has been shown to require two frameshift events during translation, contrary to one frameshift or the absence of frameshifting that appears to be common in other retroviruses. The downstream consequence relative to the formation of the three precursor protein/polypeptides (Gag, Gag-Pol, and Gag-Pol-Pro) may be a low ratio of enzyme activity to Gag protein. This may result in some viral particles containing no reverse transcriptase activity (113-115). The cell-cell transmission of HTLV-1 occurs through a structure termed the "virologic synapse". This process involves the reorientation of the infected cell relative to the uninfected cell based on alterations induced in the microtubule-organizing center. This process has been shown to occur in response, at least in part, to the activity of the Tax protein, found to be located near the microtubule-organizing center. The polarization of the infected cell relative to the uninfected cell triggers the microtubule reorientation involved in forming the virologic synapse (112, 116). The Env protein (specifically, the surface gp46 protein) from an infected cell binds to the target receptor, often the ubiquitous glucose uptake molecule Glut-1. It is postulated that surface heparin sulfate proteoglycans, and neuropilin-1 may act as receptors as well (117-119). The intracellular adhesion molecule-1 (ICAM)-1, ICAM-3, and vascular adhesion molecule (VCAM) receptors may act as cofactors for the cellular fusion (120, 121). In the interaction

between virus and DCs, the receptor DC-SIGN (dendritic cell-specific ICAM-3 grabbing non-integrin) acts as a cofactor for viral entry (122).

5.2. Proviral load

A strong indicator of disease progression from asymptomatic HTLV-1 infection to HAM/TSP is the presence of a high proviral load (18, 19, 22, 123). There is a large variation in the proviral load of HTLV-1-infected carriers, a 10- to a 100-fold increase may be observed in HAM/TSP patients compared to asymptomatic carriers (123, 124). Host genetic factors such as HLA class 1 genotypes are thought to be a factor relevant to both proviral load and CTL recognition, as the MHC class 1 alleles HLA-A*02 and HLA-Cw*08 are associated with lower proviral loads and have a protective effect on the acquisition of HAM/TSP while the HLA-B*5401 allele is associated with both a higher proviral load and risk of HAM/TSP. The alleles may be associated with CTL efficiency, as the CTL recognition of many viral epitopes contributes to anti-viral surveillance (125, 126). Although important for controlling proviral load, the CTL response is a contributor to resultant tissue damage through an overly active inflammatory response (45, 123, 125). An autoregulatory loop may develop between the proviral load and CD8⁺ T-cells. As stated earlier, the proviral load appears to stimulate the amount of proliferating CD8⁺ T cells, a large percentage of which will subsequently become infected, further increasing the proviral load (17). A CTL response is necessary to control HTLV-1, but in HAM/TSP, despite the large number of activated, circulating CTL cells, the proviral load remains elevated. It is possible that these cells are not effective, and are in fact deregulated by viral infection (44). This deregulation may be described through a three-cell model consisting of CD4⁺ T-cells, CD8⁺ T-cells, and DCs, which are able to activate a naïve CD8⁺ T cell to become a CTL (127). Before this occurs, a DC needs to encounter an antigen, migrate to the lymph nodes, and present the antigen to CD4⁺ T cells. Following recognition, the CD4⁺ T cells are activated and express a costimulatory molecule such as CD40L that may then bind to the corresponding receptor on DCs and has been shown to induce their maturation. The mature DCs may then activate CD8⁺ T-cells (44). HTLV-1 may infect all three of these cell types, and this may result in a deregulation of the resulting CTL activity (128-130). How infection may result in deregulation is not known for certain, but may be through the cellular interactions with CD4⁺ T cells. Through the use of correlational studies, Wodarz and Bangham (131) calculated that in asymptomatic carriers a positive correlation exists between the CTL response and viral load, while in patients with HAM/TSP there was no correlation. These results strongly suggest that viral load and CTL activation may be responsible for the efficacy of the CTL response (131).

5.3. Transcriptional transactivator protein Tax

A key protein regulating the progression of HAM/TSP is the HTLV-1 transcriptional transactivator, Tax. The Tax protein, encoded from the pX region of the HTLV-1 genome, has been shown to activate both viral and cellular gene expression and has been thought to escalate the pathogenesis of HTLV-1 (132). Tax possesses the capacity to repress the cellular machinery responsible for DNA repair and may promote apoptosis, the expression of proto-oncogenes, and proliferation of T cells. These characteristics contribute to T cell transformation, and subsequently to the commencement of ATL (132-142). Tax is localized in both the nucleus and cytoplasm within cells. The nuclear accumulation of Tax is promoted by a nuclear localization signal (NLS) found within the first 58 amino acids of the amino-terminus of the protein, a signal that is unique when compared to classical NLSs (143, 144) in that the signal is suspected to involve some form of conformational element in addition to the cis-acting element. In addition, Tax contains a leucine-rich nuclear export signal (NES) and has been shown to be able to shuttle to and from the cytoplasm and nucleus (143, 145). Tax may also exist extracellularly as a result of cellular apoptosis, necrosis, or through the action of specific secretory pathways (146). Experiments performed

by the selective mutation of secretory signals contained in the carboxy-terminal region of Tax, and evidence collected from the interaction of Tax with various secretory proteins, have elucidated the secretory pathway of Tax from the nucleus into the extra-cellular environment. Tax enters the secretory pathway by a leaderless system, and is secreted from cells in the regulated secretory pathway initiating in the nucleus, and in the cytoplasm traveling to the endoplasmic reticulum, golgi, post-golgi, and lastly exiting the plasma membrane (147). Extracellular Tax contributes to the hyperimmune and inflammatory response observed during the course of HAM/TSP by its transcriptional effects on neighboring cells, stimulation of immune response, and its role as an extracellular cytokine. It has also been demonstrated to accumulate in the peripheral blood and the CNS of HAM/TSP patients (42). Extracellular Tax has been shown to induce the production of TNF- α from a human neuronal cell line at a concentration that has been shown to be produced by HTLV-1-infected cells (88, 148). Release of TNF- α may result in both an autocrine and paracrine cytokine-mediated destruction of neuronal tissue. Other pathologic processes observed in HAM/TSP patients include demyelination of CNS neurons, which may also be a direct effect of extracellular Tax (88, 92). In addition to neurons, adult human microglial cells were also shown to secrete TNF- α , IL-1 β , and IL-6 in response to Tax (70). These observations correlate with additional studies demonstrating that HTLV-1-infected microglial cells secrete both TNF- α and IL-6 but not IL-1 β , suggesting that Tax may have a paracrine effect on other Tax-producing cells (70). The effects of extracellular Tax have not been limited to the CNS, primary human peripheral blood macrophages have also been shown to secrete TNF- α , IL-1, and IL-6 in response to extracellular Tax (70). Recently, cell-free Tax has been demonstrated in the CSF of HAM/TSP patients (42) indicating that Tax is available for immune recognition by APCs. Extracellular Tax released from Tax-producing cells by secretion or apoptosis and necrosis may be internalized by professional antigen presenting cells (APCs). Tax peptides presented in the context of MHC by APCs would result in lysis of Tax-expressing cells by Tax-specific CD8⁺ T cells. Either production of toxic molecules or specific cell lysis could result in significant CNS damage similar to that observed in HAM/TSP.

6. INTERMEDIATE FACTORS

6.1. Blood-brain barrier

The BBB is a tightly controlled barrier separating the circulating blood flow from the parenchyma, and is composed of three main components: a basement membrane including pericytes (a cell population which resides in the basement membrane and stabilizes blood vessel formation), specialized endothelial cells, and astrocytes (149). In order to access the BBB, leukocytes must migrate through the internal carotid arteries passing through the BBB (150). The receptor interactions of lymphocyte function-associated antigen (LFA)-1, ICAM-1, VCAM-1, and very late antigen (VLA)-4 mediate leukocyte migration through the BBB (150, 151). As part of the BBB, the blood-CSF barrier is situated in the ventricles at the site of the choroid plexus, the area that is responsible for generating the CSF. The ventricles open to the subarachnoid space, and the CSF generated is released into this space surrounding the CNS. Infiltrating leukocytes traverse the blood into the choroid plexus, and then follow the path of the CSF. The cells that cross the blood-CSF barrier are predominantly CD4⁺ T cells expressing characteristics of central memory T cells, although other lymphocytes such as CTLs also gain entry to the CNS through the internal carotid artery to the subarachnoid space, again coming in contact with the CSF (150). HTLV-1-infected lymphocytes aggregate in CNS regions such as the periventricular areas of the blood-CSF barrier, the subarachnoid space, and the thoracic and lumbar regions of the spinal cord (Figure 2).

It is thought that a small number of T lymphocyte cells patrol the CNS under normal healthy circumstances under tight immunologic control. If no antigen is encountered during surveillance, these T cells do not remain in the CNS (152). However, in inflammatory situations with the accompanying breakdown of the BBB, a large number of leukocytes are able to gain access. Experiments performed utilizing both the HTLV-1-producing T cell line, MT2, and endothelial cells containing CNS barrier characteristics have examined the mechanisms of viral infiltration into the CNS. In this model, it was found that the HTLV-1-infected MT2 cells have a greater ability to adhere to and migrate through the endothelial layer than the uninfected control lymphocytes; LFA-1, ICAM-1, and VCAM-1 molecules were also found to be upregulated (151).

6.2. Proinflammatory cytokines/chemokines

Cytokines and chemokines function as important signaling factors in the healthy CNS, but a severe disruption has been postulated to contribute to the dysfunctional host-viral immune function and pathogenesis that occurs in inflammatory diseases such as HAM/TSP. Elevated levels of the proinflammatory cytokines IFN- γ , TNF- α , IL-1, IL-6, and GM-CSF are found in the CSF of HAM/TSP patients (153-157). CTL cells are important in the reduction of the proviral load in HTLV-1-infected patients, but in patients with HAM/TSP, the amount of antigen available may be at such a level that a threshold is crossed and CTL cells are stimulated to release proinflammatory cytokines such as IFN- γ and TNF- α (46, 158, 159). Polymorphism experiments performed by Vine and Bangham (160) have recently found an association suggesting a link between the TNF- α promoter gene allele (TNF-863A) and the risk for HAM/TSP provided an individual possessed a high proviral load (160). An association between the TNF-863A allele and the HTLV-1-associated inflammatory syndrome, uveitis, has previously been established (161). Furthermore, within the same polymorphism study, other allele associations were identified as well, including a correlation with allele IL-15 +191C with respect to reducing proviral load in HTLV-1-infected HAM/TSP patients (160). As previously discussed, many of the resident CNS cells will also release cytokines when induced by extracellular Tax. The chemokines, monokine-induced by interferon- γ (MIG) and IP-10, associated with recruitment of Th1-associated lymphocytes, have been shown to be present in high levels in the serum, and positively correlate with the level of IFN- γ in HAM/TSP patients, when HAM/TSP and HTLV-1-infected asymptomatic carriers were measured as an associated group (162).

6.3. Infiltrating blood cells

Peripheral and CNS inflammation differ, in that in the CNS, lymphocyte cell infiltration is not immediate, but a delayed phenomena requiring a matter of days (64, 163, 164). Following recruitment, most lymphocytes do not directly enter the CNS parenchyma until the end stages of disease, but instead accumulate in perivascular regions, the ventricles, and under the meninges (62, 165-171). The phenotype of infiltrating lymphocytes is determined by the stage of HAM/TSP (41). During the primary stages of the disease, CD4⁺ T cells, B lymphocytes, and CD8⁺ T cells infiltrate the CNS in relatively equal numbers. The later stages of the disease are marked by the predominance of CD8⁺ T cells largely specific for Tax, circulating within the CNS, predominantly in the subarachnoid space and parenchyma (27, 34). Recently, APCs have been identified in the CNS, either as resident cells such as microglia, or as monocytes or DCs that have traversed the BBB. Parenchymal microglia may be induced to differentiate in the presence of GM-CSF and M-CSF and acquire characteristics of immature DCs (59). There are three areas where T cells may encounter APCs, the systemic immune compartment with its secondary lymphoid tissues, the CNS parenchyma with microglia and astrocytes, and the perivascular meningeal space with macrophages and DCs (172). DCs are the most potent APCs, capable of stimulating both naïve CD4⁺ T cells and CD8⁺ T cells (97). It has been postulated that DCs may be recruited

into the choroid plexus or lesion sites of the inflammatory CNS model by cytokines released from injured CNS tissue, such as GM-CSF, TNF- α , and IL-1 (173). Two subsets of DCs have been identified in humans, myeloid DCs, and lymphoid or plasmacytoid DCs. Myeloid DCs are preferentially localized to skin and mucosal tissues, and plasmacytoid DCs preferentially in the peripheral blood (174). Both subsets were found to be present in the CSF under healthy conditions, but are found in higher concentrations in inflammatory neurologic disorders (175). Myeloid DCs appear better able to stimulate CD4⁺ and CD8⁺ T cells and a Th1 response, and plasmacytoid DCs preferentially stimulate a Th2 response. HAM/TSP is predominantly a Th1-driven response while ATL is predominantly a Th2/Th3 response. Therefore, it has been proposed that myeloid DCs are preferentially infected by HTLV-1 in individuals that progress to HAM/TSP and plasmacytoid DCs are infected in individuals that develop ATL (17). DCs are implicated to play a role in the pathogenesis of HAM/TSP by the presentation of Tax to naïve CD8⁺ T cells by infected DCs, thereby activating and inducing a Tax-specific CTL response (17, 97). Infected DCs are not necessarily the primary DCs encountered, other factors are involved. Experiments performed in our laboratory have demonstrated that DCs pulsed with Tax secrete cytokines and chemokines as determined by cytokine array. These cytokines and chemokines include the Th1 cytokines, IFN- γ , IL-12, and TNF- α and the C-C chemokines eotaxin, MCP-1, and MCP-3, all released in significantly high amounts garnering at least a 2-fold increase. This Tax-induced cytokine secretion may contribute to the cellular activation and tissue damage characteristic of HAM/TSP (176). Additionally, the exposure of DCs to Tax has likewise been found to activate DCs and increase expression of CD60 and CD86 mRNA (177).

7. CONCLUSIONS AND FUTURE PERSPECTIVES

The CNS is a specialized site with limited communication between the peripheral blood immune system and its own. The capability of the CNS and the extent of the roles of individual CNS resident cells in viral and immune reactions have not been fully delineated, especially with regard to HAM/TSP. Currently, therapies to treat symptoms involve the use of steroids to control the overly active immune response while nucleoside analog reverse-transcriptase inhibitors have been shown to successfully decrease HTLV-1 proviral load. HIV-1 protease inhibitors have been tested on HTLV-1 as well, but were shown to be less effective due to variations in the HTLV-1 Gag protein (178-180). Highly active antiretroviral therapy (HAART) remains a first line of defense against retroviruses such as HIV-1, however, it is less effective in treating retroviral neurological disorders as it is not able to easily cross the BBB, so a viral reservoir remains in the CNS (181). Insights gained into the viral CNS cellular infection have predominantly been the result of experiments performed involving the *in vitro* infection of individual cell populations and *in situ* hybridization of CNS tissue. *In vitro* experiments may contribute insights but are inherently physiologically limited. The resident CNS cell populations represent a highly complex interactive compartment, thus an *in vivo* model would be much more useful in understanding the pathophysiology of HAM/TSP and associated neurologic disorders. We are currently working on the development of a transgenic mouse (C57BL/6-Tg (HLA-A2.1) model with chimeric HTLV-1 for HAM/TSP mimicking human neurologic demyelination and neuroinflammatory disorders similar to multiple sclerosis. Further research is warranted to develop a useful small animal model that could be exploited as a tool for screening and evaluation of anti-HTLV-1 molecules for improved therapy.

Acknowledgments

This work is supported by the United States Public Health Service/National Institutes of Health: USPHS/NIH 2R1 CA054559 (B. Wigdahl). P. Jain and Z. K. Khan are also supported in part by CA054559 and by faculty development funds provided by the Department of Microbiology and Immunology of the Drexel University College of Medicine.

9. REFERENCES

1. Hinuma Y, Komoda H, Chosa T, Kondo T, Kohakura M, Takenaka T, Kikuchi M, Ichimaru M, Yunoki K, Sato I, Matsuo R, Takiuchi Y, Uchino H, Hanaoka M. Antibodies to adult T-cell leukemia-virus-associated antigen (ATLA) in sera from patients with ATL and controls in Japan: a nation-wide sero-epidemiologic study. *Int J Cancer*. 1982; 29(6):631–5. [PubMed: 6980846]
2. Blattner WA, Blayney DW, Robert-Guroff M, Sarngadharan MG, Kalyanaraman VS, Sarin PS, Jaffe ES, Gallo RC. Epidemiology of human T-cell leukemia/lymphoma virus. *J Infect Dis*. 1983; 147(3):406–16. [PubMed: 6300254]
3. Blattner WA, Kalyanaraman VS, Robert-Guroff M, Lister TA, Galton DA, Sarin PS, Crawford MH, Catovsky D, Greaves M, Gallo RC. The human type-C retrovirus, HTLV, in Blacks from the Caribbean region, and relationship to adult T-cell leukemia/lymphoma. *Int J Cancer*. 1982; 30(3): 257–64. [PubMed: 6290401]
4. Reeves WC, Saxinger C, Brenes MM, Quiroz E, Clark JW, Hoh MW, Blattner WA. Human T-cell lymphotropic virus type I (HTLV-I) seroepidemiology and risk factors in metropolitan Panama. *Am J Epidemiol*. 1988; 127(3):532–9. [PubMed: 2893539]
5. Maloney EM, Ramirez H, Levin A, Blattner WA. A survey of the human T-cell lymphotropic virus type I (HTLV-I) in south-western Colombia. *Int J Cancer*. 1989; 44(3):419–23. [PubMed: 2777408]
6. Saxinger W, Blattner WA, Levine PH, Clark J, Biggar R, Hoh M, Moghissi J, Jacobs P, Wilson L, Jacobson R, et al. Human T-cell leukemia virus (HTLV-I) antibodies in Africa. *Science*. 1984; 225(4669):1473–6. [PubMed: 6089348]
7. de-The G, Giordano C, Gessain A, Howlett W, Sonan T, Akani F, Rosling H, Carton H, Mouanga Y, Caudie C, et al. Human retroviruses HTLV-I, HIV-1, and HIV-2 and neurological diseases in some equatorial areas of Africa. *J Acquir Immune Defic Syndr*. 1989; 2(6):550–6. [PubMed: 2585247]
8. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. *Proc Natl Acad Sci U S A*. 1980; 77(12):7415–9. [PubMed: 6261256]
9. de The G, Bomford R. An HTLV-I vaccine: why, how, for whom? *AIDS Res Hum Retroviruses*. 1993; 9(5):381–6. [PubMed: 8318266]
10. Edlich RF, Hill LG, Williams FM. Global epidemic of human T-cell lymphotropic virus type-I (HTLV-I): an update. *J Long Term Eff Med Implants*. 2003; 13(2):127–40. [PubMed: 14510286]
11. Hollsberg P, Hafler DA. Seminars in medicine of the Beth Israel Hospital, Boston. Pathogenesis of diseases induced by human lymphotropic virus type I infection. *N Engl J Med*. 1993; 328(16): 1173–82. [PubMed: 8455685]
12. Asquith B, Hanon E, Taylor GP, Bangham CR. Is human T-cell lymphotropic virus type I really silent? *Philos Trans R Soc Lond B Biol Sci*. 2000; 355(1400):1013–9. [PubMed: 11186302]
13. Usuku K, Sonoda S, Osame M, Yashiki S, Takahashi K, Matsumoto M, Sawada T, Tsuji K, Tara M, Igata A. HLA haplotype-linked high immune responsiveness against HTLV-I in HTLV-I-associated myelopathy: comparison with adult T-cell leukemia/lymphoma. *Ann Neurol*. 1988; 23(Suppl):S143–50. [PubMed: 2894806]
14. Daenke S, Nightingale S, Cruickshank JK, Bangham CR. Sequence variants of human T-cell lymphotropic virus type I from patients with tropical spastic paraparesis and adult T-cell leukemia do not distinguish neurological from leukemic isolates. *J Virol*. 1990; 64(3):1278–82. [PubMed: 2304144]
15. Nishimura M, McFarlin DE, Jacobson S. Sequence comparisons of HTLV-I from HAM/TSP patients and their asymptomatic spouses. *Neurology*. 1993; 43(12):2621–4. [PubMed: 7504797]
16. Niewiesk S, Daenke S, Parker CE, Taylor G, Weber J, Nightingale S, Bangham CR. The transactivator gene of human T-cell leukemia virus type I is more variable within and between healthy carriers than patients with tropical spastic paraparesis. *J Virol*. 1994; 68(10):6778–81. [PubMed: 8084014]
17. Grant C, Barmak K, Alefantis T, Yao J, Jacobson S, Wigdahl B. Human T cell leukemia virus type I and neurologic disease: events in bone marrow, peripheral blood, and central nervous system

- during normal immune surveillance and neuroinflammation. *J Cell Physiol.* 2002; 190(2):133–59. [PubMed: 11807819]
18. Gessain A, Saal F, Gout O, Daniel MT, Flandrin G, de The G, Peries J, Sigaux F. High human T-cell lymphotropic virus type I proviral DNA load with polyclonal integration in peripheral blood mononuclear cells of French West Indian, Guianese, and African patients with tropical spastic paraparesis. *Blood.* 1990; 75(2):428–33. [PubMed: 1967218]
 19. Kira J, Koyanagi Y, Yamada T, Itoyama Y, Goto I, Yamamoto N, Sasaki H, Sakaki Y. Increased HTLV-I proviral DNA in HTLV-I-associated myelopathy: a quantitative polymerase chain reaction study. *Ann Neurol.* 1991; 29(2):194–201. [PubMed: 2012389]
 20. Kubota R, Umehara F, Izumo S, Ijichi S, Matsumuro K, Yashiki S, Fujiyoshi T, Sonoda S, Osame M. HTLV-I proviral DNA amount correlates with infiltrating CD4+ lymphocytes in the spinal cord from patients with HTLV-I-associated myelopathy. *J Neuroimmunol.* 1994; 53(1):23–9. [PubMed: 7914211]
 21. Richardson JH, Edwards AJ, Cruickshank JK, Rudge P, Dalgleish AG. In vivo cellular tropism of human T-cell leukemia virus type 1. *J Virol.* 1990; 64(11):5682–7. [PubMed: 1976827]
 22. Yoshida M, Osame M, Kawai H, Toita M, Kuwasaki N, Nishida Y, Hiraki Y, Takahashi K, Nomura K, Sonoda S, et al. Increased replication of HTLV-I in HTLV-I-associated myelopathy. *Ann Neurol.* 1989; 26(3):331–5. [PubMed: 2802532]
 23. Araujo AQ, Silva MT. The HTLV-I neurological complex. *Lancet Neurol.* 2006; 5(12):1068–76. [PubMed: 17110288]
 24. Gessain A, Gout O. Chronic myelopathy associated with human T-lymphotropic virus type I (HTLV-I). *Ann Intern Med.* 1992; 117(11):933–46. [PubMed: 1443956]
 25. McKee DH, Young AC, Haeney M. Sarcoidosis and HTLV-1 infection. *J Clin Pathol.* 2005; 58(9):996–7. [PubMed: 16126888]
 26. Moore GR, Traugott U, Scheinberg LC, Raine CS. Tropical spastic paraparesis: a model of virus-induced, cytotoxic T-cell-mediated demyelination? *Ann Neurol.* 1989; 26(4):523–30. [PubMed: 2817828]
 27. Levin MC, Jacobson S. Cellular and humoral immune responses associated with HTLV-I associated myelopathy/tropical spastic paraparesis. *Ann N Y Acad Sci.* 1997; 835:142–52. [PubMed: 9616769]
 28. Araujo AQ, Andrade-Filho AS, Castro-Costa CM, Menna-Barreto M, Almeida SM. HTLV-I-associated myelopathy/tropical spastic paraparesis in Brazil: a nationwide survey. HAM/TSP Brazilian Study Group. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1998; 19(5):536–41. [PubMed: 9859969]
 29. Nakagawa M, Izumo S, Ijichi S, Kubota H, Arimura K, Kawabata M, Osame M. HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings. *J Neurovirol.* 1995; 1(1):50–61. [PubMed: 9222342]
 30. Shibasaki H, Endo C, Kuroda Y, Kakigi R, Oda K, Komine S. Clinical picture of HTLV-I associated myelopathy. *J Neurol Sci.* 1988; 87(1):15–24. [PubMed: 3193123]
 31. Lima MA, Bica RB, Araujo AQ. Gender influence on the progression of HTLV-I associated myelopathy/tropical spastic paraparesis. *J Neurol Neurosurg Psychiatry.* 2005; 76(2):294–6. [PubMed: 15654060]
 32. Araujo AQ, Leite AC, Dultra SV, Andrada-Serpa MJ. Progression of neurological disability in HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). *J Neurol Sci.* 1995; 129(2):147–51. [PubMed: 7608729]
 33. Kannagi M, Shida H, Igarashi H, Kuruma K, Murai H, Aono Y, Maruyama I, Osame M, Hattori T, Inoko H, et al. Target epitope in the Tax protein of human T-cell leukemia virus type I recognized by class I major histocompatibility complex-restricted cytotoxic T cells. *J Virol.* 1992; 66(5):2928–33. [PubMed: 1373197]
 34. Umehara F, Izumo S, Nakagawa M, Ronquillo AT, Takahashi K, Matsumuro K, Sato E, Osame M. Immunocytochemical analysis of the cellular infiltrate in the spinal cord lesions in HTLV-I-associated myelopathy. *J Neuropathol Exp Neurol.* 1993; 52(4):424–30. [PubMed: 8355031]
 35. Jacobson S, Raine CS, Mingioli ES, McFarlin DE. Isolation of an HTLV-I-like retrovirus from patients with tropical spastic paraparesis. *Nature.* 1988; 331(6156):540–3. [PubMed: 2829028]

36. Dhawan S, Weeks BS, Abbasi F, Gralnick HR, Notkins AL, Klotman ME, Yamada KM, Klotman PE. Increased expression of alpha 4 beta 1 and alpha 5 beta 1 integrins on HTLV-I-infected lymphocytes. *Virology*. 1993; 197(2):778–81. [PubMed: 7504369]
37. Furuya T, Nakamura T, Shirabe S, Nishiura Y, Tsujino A, Goto H, Nakane S, Eguchi K, Nakamura H, Nagataki S. Heightened transmigration activity of CD4-positive T cells through reconstituted basement membrane in patients with human T-lymphotropic virus type I-associated myelopathy. *Proc Assoc Am Physicians*. 1997; 109(3):228–36. [PubMed: 9154639]
38. Mogensen TH, Paludan SR. Molecular pathways in virus-induced cytokine production. *Microbiol Mol Biol Rev*. 2001; 65(1):131–50. [PubMed: 11238989]
39. Sakai JA, Nagai M, Brennan MB, Mora CA, Jacobson S. In vitro spontaneous lymphoproliferation in patients with human T-cell lymphotropic virus type I-associated neurologic disease: predominant expansion of CD8+ T cells. *Blood*. 2001; 98(5):1506–11. [PubMed: 11520801]
40. Jacobson S, McFarlin DE, Robinson S, Voskuhl R, Martin R, Brewah A, Newell AJ, Koenig S. HTLV-I-specific cytotoxic T lymphocytes in the cerebrospinal fluid of patients with HTLV-I-associated neurological disease. *Ann Neurol*. 1992; 32(5):651–7. [PubMed: 1449245]
41. Levin MC, Jacobson S. HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP): a chronic progressive neurologic disease associated with immunologically mediated damage to the central nervous system. *J Neurovirol*. 1997; 3(2):126–40. [PubMed: 9111175]
42. Cartier L, Ramirez E. Presence of HTLV-I Tax protein in cerebrospinal fluid from HAM/TSP patients. *Arch Virol*. 2005; 150(4):743–53. [PubMed: 15592888]
43. Osame M. Pathological mechanisms of human T-cell lymphotropic virus type I-associated myelopathy (HAM/TSP). *J Neurovirol*. 2002; 8(5):359–64. [PubMed: 12402162]
44. Barmak K, Harhaj EW, Wigdahl B. Mediators of central nervous system damage during the progression of human T-cell leukemia type I-associated myelopathy/tropical spastic paraparesis. *J Neurovirol*. 2003; 9(5):522–9. [PubMed: 13129766]
45. Parker CE, Daenke S, Nightingale S, Bangham CR. Activated, HTLV-1-specific cytotoxic T-lymphocytes are found in healthy seropositives as well as in patients with tropical spastic paraparesis. *Virology*. 1992; 188(2):628–36. [PubMed: 1374983]
46. Biddison WE, Kubota R, Kawanishi T, Taub DD, Cruikshank WW, Center DM, Connor EW, Utz U, Jacobson S. Human T cell leukemia virus type I (HTLV-I)-specific CD8+ CTL clones from patients with HTLV-I-associated neurologic disease secrete proinflammatory cytokines, chemokines, and matrix metalloproteinase. *J Immunol*. 1997; 159(4):2018–25. [PubMed: 9257869]
47. Selmaj K, Raine CS, Farooq M, Norton WT, Brosnan CF. Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin. *J Immunol*. 1991; 147(5):1522–9. [PubMed: 1908877]
48. Levin MC, Lee SM, Kalume F, Morcos Y, Dohan FC Jr, Hasty KA, Callaway JC, Zunt J, Desiderio D, Stuart JM. Autoimmunity due to molecular mimicry as a cause of neurological disease. *Nat Med*. 2002; 8(5):509–13. [PubMed: 11984596]
49. Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. *Nat Rev Immunol*. 2005; 5(1):69–81. [PubMed: 15630430]
50. Watabe K, Saida T, Kim SU. Human and simian glial cells infected by human T-lymphotropic virus type I in culture. *J Neuropathol Exp Neurol*. 1989; 48(6):610–9. [PubMed: 2677251]
51. Lehty TJ, Fox CH, Koenig S, Levin MC, Flerlage N, Izumo S, Sato E, Raine CS, Osame M, Jacobson S. Detection of human T-lymphotropic virus type I (HTLV-I) tax RNA in the central nervous system of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by in situ hybridization. *Ann Neurol*. 1995; 37(2):167–75. [PubMed: 7847858]
52. Hivin P, Gaudray G, Devaux C, Mesnard JM. Interaction between C/EBPbeta and Tax down-regulates human T-cell leukemia virus type I transcription. *Virology*. 2004; 318(2):556–65. [PubMed: 14972524]
53. Grant C, Nonnemacher M, Jain P, Pandya D, Irish B, Williams SC, Wigdahl B. CCAAT/enhancer-binding proteins modulate human T cell leukemia virus type 1 long terminal repeat activation. *Virology*. 2006

54. Grant C, Jain P, Nonnemacher M, Flaig KE, Irish B, Ahuja J, Alexaki A, Alefantis T, Wigdahl B. AP-1-directed human T cell leukemia virus type 1 viral gene expression during monocytic differentiation. *J Leukoc Biol.* 2006; 80(3):640–50. [PubMed: 16829632]
55. Wessner R, Yao J, Wigdahl B. Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer. *Leukemia.* 1997; 11(Suppl 3):10–3. [PubMed: 9209281]
56. Hickey WF, Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. *Science.* 1988; 239(4837):290–2. [PubMed: 3276004]
57. Bauer J, Huitinga I, Zhao W, Lassmann H, Hickey WF, Dijkstra CD. The role of macrophages, perivascular cells, and microglial cells in the pathogenesis of experimental autoimmune encephalomyelitis. *Glia.* 1995; 15(4):437–46. [PubMed: 8926037]
58. Koyanagi Y, Itoyama Y, Nakamura N, Takamatsu K, Kira J, Iwamasa T, Goto I, Yamamoto N. In vivo infection of human T-cell leukemia virus type I in non-T cells. *Virology.* 1993; 196(1):25–33. [PubMed: 8356797]
59. Santambrogio L, Belyanskaya SL, Fischer FR, Cipriani B, Brosnan CF, Ricciardi-Castagnoli P, Stern LJ, Strominger JL, Riese R. Developmental plasticity of CNS microglia. *Proc Natl Acad Sci U S A.* 2001; 98(11):6295–300. [PubMed: 11371643]
60. Town T, Nikolic V, Tan J. The microglial “activation” continuum: from innate to adaptive responses. *J Neuroinflammation.* 2005; 2:24. [PubMed: 16259628]
61. Fischer HG, Reichmann G. Brain dendritic cells and macrophages/microglia in central nervous system inflammation. *J Immunol.* 2001; 166(4):2717–26. [PubMed: 11160337]
62. Perry VH, Andersson PB, Gordon S. Macrophages and inflammation in the central nervous system. *Trends Neurosci.* 1993; 16(7):268–73. [PubMed: 7689770]
63. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. *Trends Neurosci.* 1996; 19(8):312–8. [PubMed: 8843599]
64. Carson MJ, Sutcliffe JG. Balancing function vs. self defense: the CNS as an active regulator of immune responses. *J Neurosci Res.* 1999; 55(1):1–8. [PubMed: 9890428]
65. Abe M, Umehara F, Kubota R, Moritoyo T, Izumo S, Osame M. Activation of macrophages/microglia with the calcium-binding proteins MRP14 and MRP8 is related to the lesional activities in the spinal cord of HTLV-I associated myelopathy. *J Neurol.* 1999; 246(5):358–64. [PubMed: 10399866]
66. Hoffman PM, Dhib-Jalbut S, Mikovits JA, Robbins DS, Wolf AL, Bergey GK, Lohrey NC, Weislow OS, Ruscetti FW. Human T-cell leukemia virus type I infection of monocytes and microglial cells in primary human cultures. *Proc Natl Acad Sci U S A.* 1992; 89(24):11784–8. [PubMed: 1465399]
67. Hara H, Morita M, Iwaki T, Hatae T, Itoyama Y, Kitamoto T, Akizuki S, Goto I, Watanabe T. Detection of human T lymphotropic virus type I (HTLV-I) proviral DNA and analysis of T cell receptor V beta CDR3 sequences in spinal cord lesions of HTLV-I-associated myelopathy/tropical spastic paraparesis. *J Exp Med.* 1994; 180(3):831–9. [PubMed: 8064235]
68. Kuroda Y, Matsui M, Kikuchi M, Kurohara K, Endo C, Yukitake M, Matsuda Y, Tokunaga O, Komine-Sakaki A, Kawaguchi R. In situ demonstration of the HTLV-I genome in the spinal cord of a patient with HTLV-I-associated myelopathy. *Neurology.* 1994; 44(12):2295–9. [PubMed: 7991115]
69. Moritoyo T, Reinhart TA, Moritoyo H, Sato E, Izumo S, Osame M, Haase AT. Human T-lymphotropic virus type I-associated myelopathy and tax gene expression in CD4+ T lymphocytes. *Ann Neurol.* 1996; 40(1):84–90. [PubMed: 8687197]
70. Dhib-Jalbut S, Hoffman PM, Yamabe T, Sun D, Xia J, Eisenberg H, Bergey G, Ruscetti FW. Extracellular human T-cell lymphotropic virus type I Tax protein induces cytokine production in adult human microglial cells. *Ann Neurol.* 1994; 36(5):787–90. [PubMed: 7979225]
71. Magistretti PJ, Pellerin L. Cellular bases of brain energy metabolism and their relevance to functional brain imaging: evidence for a prominent role of astrocytes. *Cereb Cortex.* 1996; 6(1):50–61. [PubMed: 8670638]
72. Gegelashvili G, Schousboe A. High affinity glutamate transporters: regulation of expression and activity. *Mol Pharmacol.* 1997; 52(1):6–15. [PubMed: 9224806]

73. Sibson NR, Dhankhar A, Mason GF, Behar KL, Rothman DL, Shulman RG. In vivo ¹³C NMR measurements of cerebral glutamine synthesis as evidence for glutamate-glutamine cycling. *Proc Natl Acad Sci U S A*. 1997; 94(6):2699–704. [PubMed: 9122259]
74. Aloisi F, Ria F, Adorini L. Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. *Immunol Today*. 2000; 21(3):141–7. [PubMed: 10689302]
75. Banerjee P, Rochford R, Antel J, Canute G, Wrzesinski S, Sieburg M, Feuer G. Proinflammatory cytokine gene induction by human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 Tax in primary human glial cells. *J Virol*. 2007; 81(4):1690–700. [PubMed: 17121800]
76. Szymocha R, Akaoka H, Dutuit M, Malcus C, Didier-Bazes M, Belin MF, Giraudon P. Human T-cell lymphotropic virus type 1-infected T lymphocytes impair catabolism and uptake of glutamate by astrocytes via Tax-1 and tumor necrosis factor alpha. *J Virol*. 2000; 74(14):6433–41. [PubMed: 10864655]
77. Weber J, Clapham P, McKeating J, Stratton M, Robey E, Weiss R. Infection of brain cells by diverse human immunodeficiency virus isolates: role of CD4 as receptor. *J Gen Virol*. 1989; 70(Pt 10):2653–60. [PubMed: 2677235]
78. Sabri F, Tresoldi E, Di Stefano M, Polo S, Monaco MC, Verani A, Fiore JR, Lusso P, Major E, Chiodi F, Scarlatti G. Nonproductive human immunodeficiency virus type 1 infection of human fetal astrocytes: independence from CD4 and major chemokine receptors. *Virology*. 1999; 264(2): 370–84. [PubMed: 10562499]
79. Chiodi F, Fuerstenberg S, Gidlund M, Asjo B, Fenyo EM. Infection of brain-derived cells with the human immunodeficiency virus. *J Virol*. 1987; 61(4):1244–7. [PubMed: 3644020]
80. Clapham PR, Weber JN, Whitby D, McIntosh K, Dalgleish AG, Maddon PJ, Deen KC, Sweet RW, Weiss RA. Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. *Nature*. 1989; 337(6205):368–70. [PubMed: 2536142]
81. Neumann M, Felber BK, Kleinschmidt A, Froese B, Erfle V, Pavlakis GN, Brack-Werner R. Restriction of human immunodeficiency virus type 1 production in a human astrocytoma cell line is associated with a cellular block in Rev function. *J Virol*. 1995; 69(4):2159–67. [PubMed: 7884864]
82. Tornatore C, Nath A, Amemiya K, Major EO. Persistent human immunodeficiency virus type 1 infection in human fetal glial cells reactivated by T-cell factor (s) or by the cytokines tumor necrosis factor alpha and interleukin-1 beta. *J Virol*. 1991; 65(11):6094–100. [PubMed: 1920627]
83. Kramer-Hammerle S, Rothenaigner I, Wolff H, Bell JE, Brack-Werner R. Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. *Virus Res*. 2005; 111(2):194–213. [PubMed: 15885841]
84. Lehky TJ, Cowan EP, Lampson LA, Jacobson S. Induction of HLA class I and class II expression in human T-lymphotropic virus type I-infected neuroblastoma cells. *J Virol*. 1994; 68(3):1854–63. [PubMed: 7906313]
85. Lehky TJ, Jacobson S. Induction of HLA class II in HTLV-I infected neuronal cell lines. *J Neurovirol*. 1995; 1(2):145–56. [PubMed: 9222353]
86. Wucherpfennig KW. Infectious triggers for inflammatory neurological diseases. *Nat Med*. 2002; 8(5):455–7. [PubMed: 11984586]
87. Bangham CR, Osame M. Cellular immune response to HTLV-1. *Oncogene*. 2005; 24(39):6035–46. [PubMed: 16155610]
88. Cowan EP, Alexander RK, Daniel S, Kashanchi F, Brady JN. Induction of tumor necrosis factor alpha in human neuronal cells by extracellular human T-cell lymphotropic virus type 1 Tax. *J Virol*. 1997; 71(9):6982–9. [PubMed: 9261427]
89. Griffiths I, Klugmann M, Anderson T, Yool D, Thomson C, Schwab MH, Schneider A, Zimmermann F, McCulloch M, Nadon N, Nave KA. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. *Science*. 1998; 280(5369):1610–3. [PubMed: 9616125]
90. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. *N Engl J Med*. 1998; 338(5):278–85. [PubMed: 9445407]

91. Tsunoda I, Fujinami RS. Inside-Out versus Outside-In models for virus induced demyelination: axonal damage triggering demyelination. *Springer Semin Immunopathol.* 2002; 24(2):105–25. [PubMed: 12503060]
92. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. *Ann Neurol.* 1988; 23(4):339–46. [PubMed: 3132891]
93. D'Souza S, Alinauskas K, McCrea E, Goodyer C, Antel JP. Differential susceptibility of human CNS-derived cell populations to TNF-dependent and independent immune-mediated injury. *J Neurosci.* 1995; 15(11):7293–300. [PubMed: 7472483]
94. Osame M, Janssen R, Kubota H, Nishitani H, Igata A, Nagataki S, Mori M, Goto I, Shimabukuro H, Khabbaz R, et al. Nationwide survey of HTLV-I-associated myelopathy in Japan: association with blood transfusion. *Ann Neurol.* 1990; 28(1):50–6. [PubMed: 2375633]
95. Koralnik IJ, Lemp JF Jr, Gallo RC, Franchini G. In vitro infection of human macrophages by human T-cell leukemia/lymphotropic virus type I (HTLV-I). *AIDS Res Hum Retroviruses.* 1992; 8(11):1845–9. [PubMed: 1489573]
96. Macatonia SE, Cruickshank JK, Rudge P, Knight SC. Dendritic cells from patients with tropical spastic paraparesis are infected with HTLV-1 and stimulate autologous lymphocyte proliferation. *AIDS Res Hum Retroviruses.* 1992; 8(9):1699–706. [PubMed: 1457215]
97. Makino M, Shimokubo S, Wakamatsu SI, Izumo S, Baba M. The role of human T-lymphotropic virus type 1 (HTLV-1)-infected dendritic cells in the development of HTLV-1-associated myelopathy/tropical spastic paraparesis. *J Virol.* 1999; 73(6):4575–81. [PubMed: 10233916]
98. Livingstone WJ, Moore M, Innes D, Bell JE, Simmonds P. Frequent infection of peripheral blood CD8-positive T-lymphocytes with HIV-1. Edinburgh Heterosexual Transmission Study Group. *Lancet.* 1996; 348(9028):649–54. [PubMed: 8782755]
99. Levin MC, Krichavsky M, Fox RJ, Lehky T, Jacobson S, Fox C, Kleghorn F, White J, Young N, Edwards RJ, Jack NE, Bartholomew C. Extensive latent retroviral infection in bone marrow of patients with HTLV-I-associated neurologic disease. *Blood.* 1997; 89(1):346–8. [PubMed: 8978312]
100. Feuer G, Fraser JK, Zack JA, Lee F, Feuer R, Chen IS. Human T-cell leukemia virus infection of human hematopoietic progenitor cells: maintenance of virus infection during differentiation in vitro and in vivo. *J Virol.* 1996; 70(6):4038–44. [PubMed: 8648741]
101. Santiago F, Clark E, Chong S, Molina C, Mozafari F, Mahieux R, Fujii M, Azimi N, Kashanchi F. Transcriptional up-regulation of the cyclin D2 gene and acquisition of new cyclin-dependent kinase partners in human T-cell leukemia virus type 1-infected cells. *J Virol.* 1999; 73(12):9917–27. [PubMed: 10559304]
102. Etoh K, Tamiya S, Yamaguchi K, Okayama A, Tsubouchi H, Ideta T, Mueller N, Takatsuki K, Matsuoka M. Persistent clonal proliferation of human T-lymphotropic virus type I-infected cells in vivo. *Cancer Res.* 1997; 57(21):4862–7. [PubMed: 9354450]
103. Clerici M, Stocks NI, Zajac RA, Boswell RN, Lucey DR, Via CS, Shearer GM. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. *J Clin Invest.* 1989; 84(6):1892–9. [PubMed: 2574188]
104. Miedema F, Petit AJ, Terpstra FG, Schattenkerk JK, de Wolf F, Al BJ, Roos M, Lange JM, Danner SA, Goudsmit J, et al. Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. *J Clin Invest.* 1988; 82(6):1908–14. [PubMed: 2974045]
105. Musey LK, Krieger JN, Hughes JP, Schacker TW, Corey L, McElrath MJ. Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. *J Infect Dis.* 1999; 180(2):278–84. [PubMed: 10395840]
106. Gurley RJ, Ikeuchi K, Byrn RA, Anderson K, Groopman JE. CD4+ lymphocyte function with early human immunodeficiency virus infection. *Proc Natl Acad Sci U S A.* 1989; 86(6):1993–7. [PubMed: 2564677]
107. Roilides E, Clerici M, DePalma L, Rubin M, Pizzo PA, Shearer GM. Helper T-cell responses in children infected with human immunodeficiency virus type 1. *J Pediatr.* 1991; 118(5):724–30. [PubMed: 1673468]

108. Groux H, Torpier G, Monte D, Mouton Y, Capron A, Ameisen JC. Activation-induced death by apoptosis in CD4⁺ T cells from human immunodeficiency virus-infected asymptomatic individuals. *J Exp Med*. 1992; 175(2):331–40. [PubMed: 1346269]
109. Meyaard L, Otto SA, Jonker RR, Mijster MJ, Keet RP, Miedema F. Programmed death of T cells in HIV-1 infection. *Science*. 1992; 257(5067):217–9. [PubMed: 1352911]
110. Fan N, Gavalchin J, Paul B, Wells KH, Lane MJ, Poiesz BJ. Infection of peripheral blood mononuclear cells and cell lines by cell-free human T-cell lymphoma/leukemia virus type I. *J Clin Microbiol*. 1992; 30(4):905–10. [PubMed: 1572977]
111. Derse D, Hill SA, Lloyd PA, Chung H, Morse BA. Examining human T-lymphotropic virus type I infection and replication by cell-free infection with recombinant virus vectors. *J Virol*. 2001; 75(18):8461–8. [PubMed: 11507191]
112. Igakura T, Stinchcombe JC, Goon PK, Taylor GP, Weber JN, Griffiths GM, Tanaka Y, Osame M, Bangham CR. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. *Science*. 2003; 299(5613):1713–6. [PubMed: 12589003]
113. Nam SH, Copeland TD, Hatanaka M, Oroszlan S. Characterization of ribosomal frameshifting for expression of pol gene products of human T-cell leukemia virus type I. *J Virol*. 1993; 67(1):196–203. [PubMed: 8416368]
114. Le Blanc I, Grange MP, Delamarre L, Rosenberg AR, Blot V, Pique C, Dokhelar MC. HTLV-1 structural proteins. *Virus Res*. 2001; 78(1–2):5–16. [PubMed: 11520576]
115. Mitchell MS, Tozser J, Princler G, Lloyd PA, Auth A, Derse D. Synthesis, processing, and composition of the virion-associated HTLV-1 reverse transcriptase. *J Biol Chem*. 2006; 281(7):3964–71. [PubMed: 16368688]
116. Nejmeddine M, Barnard AL, Tanaka Y, Taylor GP, Bangham CR. Human T-lymphotropic virus, type 1, tax protein triggers microtubule reorientation in the virological synapse. *J Biol Chem*. 2005; 280(33):29653–60. [PubMed: 15975923]
117. Overbaugh J. HTLV-1 sweet-talks its way into cells. *Nat Med*. 2004; 10(1):20–1. [PubMed: 14702624]
118. Takenouchi N, Jones KS, Lisinski I, Fugo K, Yao K, Cushman SW, Ruscetti FW, Jacobson S. GLUT1 is not the primary binding receptor but is associated with cell-to-cell transmission of human T-cell leukemia virus type 1. *J Virol*. 2007; 81(3):1506–10. [PubMed: 17108050]
119. Ghez D, Lepelletier Y, Lambert S, Fourneau JM, Blot V, Janvier S, Arnulf B, van Endert PM, Heveker N, Pique C, Hermine O. Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry. *J Virol*. 2006; 80(14):6844–54. [PubMed: 16809290]
120. Hildreth JE, Subramaniam A, Hampton RA. Human T-cell lymphotropic virus type 1 (HTLV-1)-induced syncytium formation mediated by vascular cell adhesion molecule-1: evidence for involvement of cell adhesion molecules in HTLV-1 biology. *J Virol*. 1997; 71(2):1173–80. [PubMed: 8995639]
121. Daenke S, McCracken SA, Booth S. Human T-cell leukaemia/lymphoma virus type 1 syncytium formation is regulated in a cell-specific manner by ICAM-1, ICAM-3 and VCAM-1 and can be inhibited by antibodies to integrin beta2 or beta7. *J Gen Virol*. 1999; 80(Pt 6):1429–36. [PubMed: 10374960]
122. Ceccaldi PE, Delebecque F, Prevost MC, Moris A, Abastado JP, Gessain A, Schwartz O, Ozden S. DC-SIGN facilitates fusion of dendritic cells with human T-cell leukemia virus type 1-infected cells. *J Virol*. 2006; 80(10):4771–80. [PubMed: 16641270]
123. Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Moritoyo T, Hashiguchi S, Ichinose M, Bangham CR, Izumo S, Osame M. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. *J Neurovirol*. 1998; 4(6):586–93. [PubMed: 10065900]
124. Bangham CR. Human T-cell leukaemia virus type I and neurological disease. *Curr Opin Neurobiol*. 1993; 3(5):773–8. [PubMed: 8260828]
125. Jeffery KJ, Usuku K, Hall SE, Matsumoto W, Taylor GP, Procter J, Bunce M, Ogg GS, Welsh KI, Weber JN, Lloyd AL, Nowak MA, Nagai M, Kodama D, Izumo S, Osame M, Bangham CR. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of

- HTLV-I-associated myelopathy. *Proc Natl Acad Sci U S A*. 1999; 96(7):3848–53. [PubMed: 10097126]
126. Jeffery KJ, Siddiqui AA, Bunce M, Lloyd AL, Vine AM, Witkover AD, Izumo S, Usuku K, Welsh KI, Osame M, Bangham CR. The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. *J Immunol*. 2000; 165(12): 7278–84. [PubMed: 11120862]
 127. Guernonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. *Annu Rev Immunol*. 2002; 20:621–67. [PubMed: 11861614]
 128. Hanon E, Stinchcombe JC, Saito M, Asquith BE, Taylor GP, Tanaka Y, Weber JN, Griffiths GM, Bangham CR. Fratricide among CD8 (+) T lymphocytes naturally infected with human T cell lymphotropic virus type I. *Immunity*. 2000; 13(5):657–64. [PubMed: 11114378]
 129. Nagai M, Brennan MB, Sakai JA, Mora CA, Jacobson S. CD8 (+) T cells are an in vivo reservoir for human T-cell lymphotropic virus type I. *Blood*. 2001; 98(6):1858–61. [PubMed: 11535522]
 130. Ali A, Patterson S, Cruickshank K, Rudge P, Dalgleish AG, Knight SC. Dendritic cells infected in vitro with human T cell leukaemia/lymphoma virus type-1 (HTLV-1); enhanced lymphocytic proliferation and tropical spastic paraparesis. *Clin Exp Immunol*. 1993; 94(1):32–7. [PubMed: 8403513]
 131. Wodarz D, Hall SE, Usuku K, Osame M, Ogg GS, McMichael AJ, Nowak MA, Bangham CR. Cytotoxic T-cell abundance and virus load in human immunodeficiency virus type 1 and human T-cell leukaemia virus type 1. *Proc Biol Sci*. 2001; 268(1473):1215–21. [PubMed: 11410146]
 132. Barmak K, Harhaj E, Grant C, Alefantis T, Wigdahl B. Human T cell leukemia virus type I-induced disease: pathways to cancer and neurodegeneration. *Virology*. 2003; 308(1):1–12. [PubMed: 12706085]
 133. Crenon I, Beraud C, Simard P, Montagne J, Veschambre P, Jalinot P. The transcriptionally active factors mediating the effect of the HTLV-I Tax transactivator on the IL-2R alpha kappa B enhancer include the product of the c-rel proto-oncogene. *Oncogene*. 1993; 8(4):867–75. [PubMed: 8455941]
 134. Kao SY, Marriott SJ. Disruption of nucleotide excision repair by the human T-cell leukemia virus type 1 Tax protein. *J Virol*. 1999; 73(5):4299–304. [PubMed: 10196328]
 135. Laherty CD, Perkins ND, Dixit VM. Human T cell leukemia virus type I Tax and phorbol 12-myristate 13-acetate induce expression of the A20 zinc finger protein by distinct mechanisms involving nuclear factor kappa B. *J Biol Chem*. 1993; 268(7):5032–9. [PubMed: 8444879]
 136. Brauweiler A, Garrus JE, Reed JC, Nyborg JK. Repression of bax gene expression by the HTLV-1 Tax protein: implications for suppression of apoptosis in virally infected cells. *Virology*. 1997; 231(1):135–40. [PubMed: 9143312]
 137. Uittenbogaard MN, Armstrong AP, Chiaramello A, Nyborg JK. Human T-cell leukemia virus type I Tax protein represses gene expression through the basic helix-loop-helix family of transcription factors. *J Biol Chem*. 1994; 269(36):22466–9. [PubMed: 8077190]
 138. Uittenbogaard MN, Giebler HA, Reisman D, Nyborg JK. Transcriptional repression of p53 by human T-cell leukemia virus type I Tax protein. *J Biol Chem*. 1995; 270(48):28503–6. [PubMed: 7499359]
 139. Azimi N, Brown K, Bamford RN, Tagaya Y, Siebenlist U, Waldmann TA. Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-kappaB site. *Proc Natl Acad Sci U S A*. 1998; 95(5):2452–7. [PubMed: 9482906]
 140. Ballard DW, Bohnlein E, Lowenthal JW, Wano Y, Franza BR, Greene WC. HTLV-I tax induces cellular proteins that activate the kappa B element in the IL-2 receptor alpha gene. *Science*. 1988; 241(4873):1652–5. [PubMed: 2843985]
 141. Good L, Maggirwar SB, Sun SC. Activation of the IL-2 gene promoter by HTLV-I tax involves induction of NF-AT complexes bound to the CD28-responsive element. *Embo J*. 1996; 15(14): 3744–50. [PubMed: 8670878]
 142. Mariner JM, Lantz V, Waldmann TA, Azimi N. Human T cell lymphotropic virus type I Tax activates IL-15R alpha gene expression through an NF-kappa B site. *J Immunol*. 2001; 166(4): 2602–9. [PubMed: 11160322]

143. Smith MR, Greene WC. Characterization of a novel nuclear localization signal in the HTLV-I tax transactivator protein. *Virology*. 1992; 187(1):316–20. [PubMed: 1736534]
144. Gitlin SD, Lindholm PF, Marriott SJ, Brady JN. Transdominant human T-cell lymphotropic virus type I TAX1 mutant that fails to localize to the nucleus. *J Virol*. 1991; 65(5):2612–21. [PubMed: 2016773]
145. Alefantis T, Barmak K, Harhaj EW, Grant C, Wigdahl B. Characterization of a nuclear export signal within the human T cell leukemia virus type I transactivator protein Tax. *J Biol Chem*. 2003; 278(24):21814–22. [PubMed: 12670929]
146. Alefantis T, Mostoller K, Jain P, Harhaj E, Grant C, Wigdahl B. Secretion of the human T cell leukemia virus type I transactivator protein tax. *J Biol Chem*. 2005; 280(17):17353–62. [PubMed: 15659397]
147. Jain P, Ahuja J, Khan ZK, Shimizu S, Meucci O, Jennings SR, Wigdahl B. Modulation of dendritic cell maturation and function by the Tax protein of human T cell leukemia virus type 1. *J Leukoc Biol*. 2007; 82(1):44–56. [PubMed: 17442856]
148. Brady JN. Extracellular Tax1 protein stimulates NF- κ B and expression of NF- κ B-responsive Ig kappa and TNF beta genes in lymphoid cells. *AIDS Res Hum Retroviruses*. 1992; 8(5):724–7. [PubMed: 1515222]
149. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. *Neurobiol Dis*. 2004; 16(1):1–13. [PubMed: 15207256]
150. Ransohoff RM, Kivisakk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. *Nat Rev Immunol*. 2003; 3(7):569–81. [PubMed: 12876559]
151. Romero IA, Prevost MC, Perret E, Adamson P, Greenwood J, Couraud PO, Ozden S. Interactions between brain endothelial cells and human T-cell leukemia virus type 1-infected lymphocytes: mechanisms of viral entry into the central nervous system. *J Virol*. 2000; 74(13):6021–30. [PubMed: 10846084]
152. Merrill JE, Benveniste EN. Cytokines in inflammatory brain lesions: helpful and harmful. *Trends Neurosci*. 1996; 19(8):331–8. [PubMed: 8843602]
153. Kuroda Y, Matsui M. Cerebrospinal fluid interferon-gamma is increased in HTLV-I-associated myelopathy. *J Neuroimmunol*. 1993; 42(2):223–6. [PubMed: 8429106]
154. Kuroda Y, Matsui M, Takashima H, Kurohara K. Granulocyte-macrophage colony-stimulating factor and interleukin-1 increase in cerebrospinal fluid, but not in serum, of HTLV-I-associated myelopathy. *J Neuroimmunol*. 1993; 45(1–2):133–6. [PubMed: 8331158]
155. Nishimoto N, Yoshizaki K, Eiraku N, Machigashira K, Tagoh H, Ogata A, Kuritani T, Osame M, Kishimoto T. Elevated levels of interleukin-6 in serum and cerebrospinal fluid of HTLV-I-associated myelopathy/tropical spastic paraparesis. *J Neurol Sci*. 1990; 97(2–3):183–93. [PubMed: 2401896]
156. Ohbo K, Sugamura K, Sekizawa T, Kogure K. Interleukin-6 in cerebrospinal fluid of HTLV-I-associated myelopathy. *Neurology*. 1991; 41(4):594–5. [PubMed: 2011262]
157. Takenouchi N, Yao K, Jacobson S. Immunopathogenesis of HTLV-I associated neurologic disease: molecular, histopathologic, and immunologic approaches. *Front Biosci*. 2004; 9:2527–39. [PubMed: 15353305]
158. Asquith B, Bangham CR. The role of cytotoxic T lymphocytes in human T-cell lymphotropic virus type 1 infection. *J Theor Biol*. 2000; 207(1):65–79. [PubMed: 11027480]
159. Hanon E, Goon P, Taylor GP, Hasegawa H, Tanaka Y, Weber JN, Bangham CR. High production of interferon gamma but not interleukin-2 by human T-lymphotropic virus type I-infected peripheral blood mononuclear cells. *Blood*. 2001; 98(3):721–6. [PubMed: 11468172]
160. Vine AM, Witkover AD, Lloyd AL, Jeffery KJ, Siddiqui A, Marshall SE, Bunce M, Eiraku N, Izumo S, Usuku K, Osame M, Bangham CR. Polygenic control of human T lymphotropic virus type I (HTLV-I) provirus load and the risk of HTLV-I-associated myelopathy/tropical spastic paraparesis. *J Infect Dis*. 2002; 186(7):932–9. [PubMed: 12232833]
161. Seki N, Yamaguchi K, Yamada A, Kamizono S, Sugita S, Taguchi C, Matsuoka M, Matsumoto H, Nishizaka S, Itoh K, Mochizuki M. Polymorphism of the 5'-flanking region of the tumor necrosis factor (TNF)-alpha gene and susceptibility to human T-cell lymphotropic virus type I (HTLV-I) uveitis. *J Infect Dis*. 1999; 180(3):880–3. [PubMed: 10438385]

162. Guerreiro JB, Santos SB, Morgan DJ, Porto AF, Muniz AL, Ho JL, Teixeira AL Jr, Teixeira MM, Carvalho EM. Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)/tropical spastic paraparesis (HAM/TSP) disease from HTLV-1 carrier state. *Clin Exp Immunol*. 2006; 145(2):296–301. [PubMed: 16879249]
163. Bell MD, Taub DD, Perry VH. Overriding the brain's intrinsic resistance to leukocyte recruitment with intraparenchymal injections of recombinant chemokines. *Neuroscience*. 1996; 74(1):283–92. [PubMed: 8843093]
164. Matyszak MK, Townsend MJ, Perry VH. Ultrastructural studies of an immune-mediated inflammatory response in the CNS parenchyma directed against a non-CNS antigen. *Neuroscience*. 1997; 78(2):549–60. [PubMed: 9145809]
165. Goverman J, Woods A, Larson L, Weiner LP, Hood L, Zaller DM. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. *Cell*. 1993; 72(4):551–60. [PubMed: 7679952]
166. Morrissey SP, Stodal H, Zettl U, Simonis C, Jung S, Kiefer R, Lassmann H, Hartung HP, Haase A, Toyka KV. In vivo MRI and its histological correlates in acute adoptive transfer experimental allergic encephalomyelitis. Quantification of inflammation and oedema. *Brain*. 1996; 119(Pt 1): 239–48. [PubMed: 8624685]
167. Steinman L. A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. *Proc Natl Acad Sci U S A*. 1996; 93(6): 2253–6. [PubMed: 8637858]
168. Gay FW, Drye TJ, Dick GW, Esiri MM. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. *Brain*. 1997; 120(Pt 8):1461–83. [PubMed: 9278635]
169. Popovich PG, Wei P, Stokes BT. Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. *J Comp Neurol*. 1997; 377(3):443–64. [PubMed: 8989657]
170. Stalder AK, Carson MJ, Pagenstecher A, Asensio VC, Kincaid C, Benedict M, Powell HC, Masliah E, Campbell IL. Late-onset chronic inflammatory encephalopathy in immune-competent and severe combined immune-deficient (SCID) mice with astrocyte-targeted expression of tumor necrosis factor. *Am J Pathol*. 1998; 153(3):767–83. [PubMed: 9736027]
171. Tran EH, Hoekstra K, van Rooijen N, Dijkstra CD, Owens T. Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice. *J Immunol*. 1998; 161(7): 3767–75. [PubMed: 9759903]
172. Greter M, Heppner FL, Lemos MP, Odermatt BM, Goebels N, Laufer T, Noelle RJ, Becher B. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. *Nat Med*. 2005; 11(3):328–34. [PubMed: 15735653]
173. Matyszak MK, Perry VH. The potential role of dendritic cells in immune-mediated inflammatory diseases in the central nervous system. *Neuroscience*. 1996; 74(2):599–608. [PubMed: 8865208]
174. Liu YJ, Kanzler H, Soumelis V, Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. *Nat Immunol*. 2001; 2(7):585–9. [PubMed: 11429541]
175. Pashenkov M, Huang YM, Kostulas V, Haglund M, Soderstrom M, Link H. Two subsets of dendritic cells are present in human cerebrospinal fluid. *Brain*. 2001; 124(Pt 3):480–92. [PubMed: 11222448]
176. Ahuja J, Lepoutre V, Wigdahl B, Khan ZK, Jain P. Induction of pro-inflammatory cytokines by human T-cell leukemia virus type-1 Tax protein as determined by multiplexed cytokine protein array analyses of human dendritic cells. *Biomed Pharmacother*. 2007; 61(4):201–8. [PubMed: 17391906]
177. Mostoller K, Norbury CC, Jain P, Wigdahl B. Human T-cell leukemia virus type I Tax induces the expression of dendritic cell markers associated with maturation and activation. *J Neurovirol*. 2004; 10(6):358–71. [PubMed: 15765807]
178. Hill SA, Lloyd PA, McDonald S, Wykoff J, Derse D. Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors. *J Infect Dis*. 2003; 188(3):424–7. [PubMed: 12870124]

179. Machuca A, Rodes B, Soriano V. The effect of antiretroviral therapy on HTLV infection. *Virus Res.* 2001; 78(1–2):93–100. [PubMed: 11520583]
180. Taylor GP, Hall SE, Navarrete S, Michie CA, Davis R, Witkover AD, Rossor M, Nowak MA, Rudge P, Matutes E, Bangham CR, Weber JN. Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy. *J Virol.* 1999; 73(12):10289–95. [PubMed: 10559346]
181. Enting RH, Hoetelmans RM, Lange JM, Burger DM, Beijnen JH, Portegies P. Antiretroviral drugs and the central nervous system. *AIDS.* 1998; 12(15):1941–55. [PubMed: 9814862]

Figure 1.

Resident CNS cells potentially involved in the genesis of HAM/TSP. The selectively permeable blood-brain barrier composed of endothelial cells, pericytes, and astrocytes is first penetrated by an HTLV-1-infected cell of lymphocytic or possibly monocytic origin. Spreading throughout the CNS, infection causes the release of the Tax protein as well as inflammatory cytokines that are responsible for demyelination and neuronal damage, causing symptomatic advancement of HAM/TSP.

Figure 2.

Areas of lymphocyte migration. (A) Regulatory lymphocytes and HTLV-1-infected lymphocytes may gain entry into the CNS through the choroid plexus BBB interface. The vesicles in the subarachnoid space are fenestrated, therefore lymphocytes are found to aggregate in this space. (B) Activated, HTLV-1-infected lymphocytes may gain entry to the CNS through the BBB and aggregate at the perivascular space. (C) Representation of a cross-section of the thoracic spinal cord. Lymphocytes infiltrate the thoracic spinal cord at areas of inflammation and demyelination, localized to the lateral areas near the corticospinal tract.

Table 1

Host and viral factors in HAM/TSP neurological pathology

Cell type	HAM/TSP		
	Clinical Pathology	Susceptibility to Infection	Cytokine/Chemokine
Macrophages/Microglia	Reactive gliosis (65)	In vitro (62)	TNF- α , IL-6, IL-1 β (66)
Astrocytes	Reactive gliosis (65)	Restricted infection (51)	TNF- α , TNF- β , IL-1 α , IL- β , IL-6, MMPs (71, 72, 90)
Neurons	Axonal dystrophy (65)	In vitro (80, 81)	TNF- α (84)
Oligodendrocytes	Demyelination (65)	Not demonstrated	IL-1 β , TNF- α , TNF- β , IL-6 (71)